Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India
Tóm tắt
In this cross-sectional study, we evaluated the efficiency of the plasma of 38 antiretroviral-naïve HIV-1-infected children from northern India against a standard panel of pseudoviruses (3 clade C and 3 clade B) by TZM-bl assay. Neutralization potential was observed to a variable extent, with a potency ranging up to reciprocal ID50 titers of 1967. Cross-neutralization was observed in 28.9 % (11/38) of the children. There was a significant positive correlation between viremia and neutralization efficiency against two of the viruses studied (Du172 r = 0.49; p = 0.007 and RHPA r = 0.47; p = 0.01), suggesting that persistent antigenic stimulation is necessary for the generation of broadly neutralizing antibody responses in these children. Further mapping of the epitope specificities of the neutralization determinants in the polyclonal plasma would provide important information for immunogen design.
Tài liệu tham khảo
Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM, Jalalian-Lechak Z, John-Stewart G, Overbaugh J (2011) The breadth and potency of passively acquired human immunodeficiency virus type 1 specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol 85:5252–5261
Cagigi A, Nilsson A, Pensieroso S, Chiodi F (2010) Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 10:499–503
Moir S, Fauci AS (2009) B cells in HIV infection and disease. Nat Rev Immunol 9:235–245
Verkoczy L, Kelsoe G, Moody MA, Haynes BF (2011) Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 23:383–390
Girard MP, Osmanov S, Assossou OM, Kieny MP (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 29:6191–6218
Gonzalez N, Alvarez A, Alcami J (2010) Broadly neutralizing antibodies and their significance for HIV-1 vaccines. Curr HIV Res 8:602–612
Prakash SS, Andrabi R, Kumar R, Kabra SK, Lodha R, Vajpayee M, Luthra K (2011) Binding antibody responses to the immunogenic regions of viral envelope in HIV-1 infected Indian children. Viral Immunol 24:463–469
Prakash SS, Chaudhary AK, Lodha R, Kabra SK, Vajpayee M, Hazarika A, Bagga B, Luthra K (2011) Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children. Viral Immunol 24:409–413
Montefiori DC (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485:395–405
Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbet PB, Self SG, Korber BT, Montefiori DC, Mascola JR (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439–1452
Prakash SS, Kalra R, Lodha R, Kabra SK, Luthra K (2012) Diversity of HIV type 1 envelope (V3-V5) sequence in HIV type 1-infected Indian children. AIDS Res Hum Retroviruses 28:505–509
Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7:e1001251
Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK, Redfield RR (2011) Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr 57:9–15